A meta-analysis of 1-year outcomes of transcatheter versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis

作     者：Aaqib H Malik Syed Zaid Hasan Ahmad Joshua Goldberg Tanya Dutta Cenap Undemir Martin Cohen Wilbert S Aronow Steven L Lansman Aaqib H Malik;Syed Zaid;Hasan Ahmad;Joshua Goldberg;Tanya Dutta;Cenap Undemir;Martin Cohen;Wilbert S.Aronow;Steven L Lansman

作者机构：Department of MedicineWestchester Medical Center and New York Medical CollegeValhallaNYUSA Department of CardiologyWestchester Medical Center and New York Medical CollegeValhallaNYUSA Section of Cardiothoracic SurgeryDepartment of SurgeryWestchester Medical CenterValhallaNew YorkUSA 

出 版 物：《Journal of Geriatric Cardiology》 (老年心脏病学杂志（英文版）)

年 卷 期：2020年第17卷第1期

页      面：43-50,I0008-I0010页

核心收录：

学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学] 

基　　金：Part of this manuscript was presented as moderated poster at TCT 2019 in San Francisco.Malik A,Zaid S,Ahmad H,Goldberg J,Dutta T,Undemir C,Cohen M,Aronow W,Lansman S,Tang G.TCT-734 Transcatheter Compared to Surgical Aortic Valve Replacement in Patients With Low Surgical Risk:A Meta-Analysis of All R 74(13 Supplement):B720.http://www.onlinejacc.org/content/74/13 _Supplement/B720.abstract.All authors have no conflicts of interest to declare 

主　　题：Aortic stenosis Low surgical risk Meta-analysis Transcatheter aortic valve replacement 

摘      要：Background Transcatheter aortic valve replacement(TAVR)for the treatment symptomatic severe aortic stenosis(AS)is indicated in patients with intermediate or higher surgical *** trials showed TAVR,and surgical aortic valve replacement(SAVR)perform similarly at 1-year for the composite outcomes of mortality,stroke and *** performed a comprehensive meta-analysis to compare individual outcomes at 1-year for TAVR compared to SAVR in low-risk *** Pub Med,Embase,and Cochrane central were searched for all the randomized controlled trials(RCTs)that reported 1-year comparative outcomes of TAVR and surgical aortic valve replacement(SAVR).Our conclusions are based upon the random-effects model using Der Simonian-Laird *** Data from 4 trials and 2887 randomized patients showed that TAVR had lower rates of all-cause mortality,cardiovascular mortality,and atrial fibrillation compared to SAVR at 1-year follow-up(P0.05 for all).Also,TAVR was also associated with a significantly higher risk of permanent pacemaker implantation and moderate-severe paravalvular leak(P0.05).Conclusions The latest randomised trial data demonstrates that in short-term,TAVR is safe and effective in reducing all-cause mortality or *** follow-up of RCTs is needed to determine the durability of clinical benefits in TAVR over SAVR in low-risk patients.